Novo Nordisk A/S (NVO) — Stock Price, Chart & Analysis
Novo Nordisk A/S (NVO) is a Healthcare stock currently trading at $100, up 0.00% on the day. It carries a market capitalization of $208.92B and a trailing P/E ratio of 11.39. Over the past 52 weeks, NVO has traded between $35.12 and $64.16. Novo Nordisk A/S pays a dividend yielding 3.9%. View the live NVO chart, technical opinion, analyst ratings, fundamentals and latest news below.
Novo Nordisk A/S (NVO) key data
| Price | $100 |
| Change (today) | +0.00% |
| Previous close | $100 |
| Market cap | $208.92B |
| P/E ratio (TTM) | 11.39 |
| EPS (TTM) | $4.15 |
| Dividend yield | 3.9% |
| 52-week high | $64.16 |
| 52-week low | $35.12 |
| Beta | 0.35 |
| Avg. volume | 12.63M |
| Sector | Healthcare |
| Industry | Drug Manufacturers - General |
Frequently asked questions about Novo Nordisk A/S (NVO)
How much does one share of Novo Nordisk A/S cost?
As of the latest update, one share of Novo Nordisk A/S (NVO) trades at $100 (+0.00% today).
What is Novo Nordisk A/S's market cap?
Novo Nordisk A/S has a market capitalization of approximately $208.92B.
What is Novo Nordisk A/S's P/E ratio?
Novo Nordisk A/S has a trailing price-to-earnings (P/E) ratio of 11.39.
What is Novo Nordisk A/S's earnings per share (EPS)?
Novo Nordisk A/S's trailing twelve-month EPS is $4.15.
Does Novo Nordisk A/S pay a dividend?
Yes — Novo Nordisk A/S pays a dividend with a yield of 3.9% ($1.80 per share annually).
What is Novo Nordisk A/S's 52-week trading range?
Over the past year, NVO has traded between $35.12 and $64.16.
What is the analyst price target for Novo Nordisk A/S?
The mean analyst price target for Novo Nordisk A/S is $47.32. This is informational only and not investment advice.
Latest Novo Nordisk A/S (NVO) news
- Eli Lilly's Timing of the FDA Filing of Its Next Weight-Loss Drug Is Now Official -- and Novo Nordisk Has a ProblemNews · Aug 7, 2026
- Scholar Rock Announces FDA Review of Apitegromab Biologics License Application (BLA) for Spinal Muscular Atrophy (SMA) to Progress with Second Fill-Finish Facility; Approval Decision Anticipated by September 30, 2026 Action DateNews · Aug 7, 2026
- Novo Nordisk Stock Rises After GLP-1 Antitrust WinNews · Aug 7, 2026
- Pfizer's Next Weight-Loss Weapon: How Berobenatide Stacks Up Against Novo Nordisk's Wegovy and Eli Lilly's ZepboundNews · Aug 7, 2026
- PRTA's Q2 Loss Narrower Than Expected, Pipeline Progress in FocusNews · Aug 7, 2026
- Stock Market Rally Powers Ahead; SpaceX, Palantir, Sandisk Are Key Earnings Movers: Weekly ReviewNews · Aug 7, 2026
Headlines via Yahoo Finance and publishers — click through to read each story at its source.
Loading the live NVO dashboard…